Form 4: Avidity Biosciences' Chief Program Officer Exercises Options and Sells Shares

Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, exercised stock options and sold shares on May 1, 2025, according to a Form 4 filing with the SEC.

Summary

• On May 1, 2025, Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, exercised stock options to acquire 5,875 shares of common stock at a price of $16.65 per share.
• Simultaneously, Gallagher sold 5,875 shares of common stock at a weighted-average price of $32.3956, with individual sales ranging from $31.46 to $32.99.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Gallagher directly owns 50,554 shares of Avidity Biosciences common stock and holds options for 28,471 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the actions of company executives. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans.

Stakeholder Impact

• Shareholders are informed about insider transactions, which can influence investor sentiment.
• The transactions have a minor impact on the overall share supply and demand.

Key Dates

Keywords

Avidity Biosciences, Kathleen P. Gallagher, stock options, Form 4, SEC, Rule 10b5-1, insider trading, RNA